908 Devices Inc. (MASS)
NASDAQ: MASS · Real-Time Price · USD
7.43
-0.37 (-4.74%)
Nov 7, 2025, 2:09 PM EST - Market open
908 Devices Revenue
908 Devices had revenue of $13.04M in the quarter ending June 30, 2025, with 13.72% growth. This brings the company's revenue in the last twelve months to $65.56M, up 37.93% year-over-year. In the year 2024, 908 Devices had annual revenue of $59.63M with 18.72% growth.
Revenue (ttm)
$65.56M
Revenue Growth
+37.93%
P/S Ratio
4.19
Revenue / Employee
$266,504
Employees
246
Market Cap
268.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 59.63M | 9.40M | 18.72% |
| Dec 31, 2023 | 50.23M | 3.38M | 7.21% |
| Dec 31, 2022 | 46.85M | 4.65M | 11.01% |
| Dec 31, 2021 | 42.21M | 15.31M | 56.93% |
| Dec 31, 2020 | 26.89M | 8.92M | 49.64% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MASS News
- 8 days ago - 908 Devices to Participate in Upcoming Investor Conferences - Business Wire
- 10 days ago - United States Coast Guard Purchases 908 Devices' Handheld Mass Spec Devices for Chemical Threat Identification - Business Wire
- 16 days ago - 908 Devices to Report Third Quarter 2025 Financial Results on November 10, 2025 - Business Wire
- 22 days ago - United States Marine Corps Purchases 908 Devices' XplorIR Gas Identification Devices - Business Wire
- 3 months ago - 908 Devices Inc. (MASS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - 908 Devices Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Outlook - Business Wire
- 3 months ago - 908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors - Business Wire
- 3 months ago - 908 Devices to Participate in the Canaccord Genuity 45th Annual Growth Conference - Business Wire